Hikma Pharmaceuticals (LON:HIK) Given “Buy” Rating at Citigroup

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reissued by stock analysts at Citigroup in a report released on Thursday,Digital Look reports.

Several other brokerages have also issued reports on HIK. Berenberg Bank reaffirmed a “buy” rating and set a GBX 1,800 price target on shares of Hikma Pharmaceuticals in a research note on Tuesday, April 28th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 195 price objective on shares of Hikma Pharmaceuticals in a report on Monday, June 22nd. Finally, Jefferies Financial Group upped their target price on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Hikma Pharmaceuticals presently has an average rating of “Buy” and an average target price of GBX 1,687.

Hikma Pharmaceuticals Stock Performance

Hikma Pharmaceuticals stock opened at GBX 1,516 on Thursday. Hikma Pharmaceuticals has a fifty-two week low of GBX 1,187 and a fifty-two week high of GBX 2,052. The company has a debt-to-equity ratio of 61.84, a quick ratio of 1.27 and a current ratio of 1.82. The stock has a market cap of £3.19 billion, a P/E ratio of 8.38, a price-to-earnings-growth ratio of 2.38 and a beta of 0.65. The firm’s fifty day moving average price is GBX 1,487.53 and its 200-day moving average price is GBX 1,448.63.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.